Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

sands) Three MonthsEnded September 30,Nine MonthsEnded September 30,2013201220132012Revenues

$

7,678$

4,282$

25,817$

14,689Operating expenses:Research and development

4,4848,16920,15330,120General and administrative

3,0761,2307,0494,533Gain on sale of kinase profiling services business

(2,500)(480)(2,500)(1,600)Total operating expenses

5,0608,91924,70233,053Income (loss) from operations

2,618(4,637)1,115(18,364)Other expenses, net

(8,687)(2,028)(10,326)(3,604)Consolidated net loss

$

(6,069)$

(6,665)$

(9,211)$

(21,968) Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Balance Sheets(in thousands) September 30,2013December 31,2012(unaudited)Cash and cash equivalents$

78,856$

17,481Other assets1,0941,948Property and equipment, net816560Total assets$

80,766$

19,989Accounts payable, accrued expenses and other liabilities

$

6,397$

12,923Deferred revenue—20,671Warrant liabilities15,62310,540Redeemable non-controlling interest—3,323Convertible preferred stock—170,778Stockholders' equity (deficit)58,746(198,246)Total liabilities and stockholders' equity$

80,766$

19,989 Ambit Contacts: Marcy Graham

Andrew McDonald, Ph.D.Executive Director, Investor Relations & Corp CommLifeSci Advisors, LLCAmbit Biosciences, Inc.

Founding Partner858-334-2125

646-597-6987mgraham@ambitbio.com

andrew@lifesciadvisors.com 


'/>"/>
SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY) is to present ... in patients with metastatic renal cancer at the ASCO ... . The data will be presented by Dr. ... Cancer Center in California in ... identifies Ferritin and IL-8 as two baseline biomarkers that ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... LONDON, June 26, 2011 The pharmaceutical industry spent less on ... three years, according to data released today from the 2011 ... Thomson Reuters business. Key highlights from the ... new molecular entities (NMEs) were launched on the global market in ...
... 2011 Cebix Incorporated announced today that preclinical data ... (CBX129801), demonstrated a half-life of three days as compared ... impairment in nerve conduction velocity, a measure of the ... in an animal model of diabetic peripheral neuropathy. Additionally, ...
... Netherlands, June 24, 2011 /PRNewswire-iReach/ -- ...  announced today the completion of a non-exclusive research ... ("Lilly"), a global pharmaceutical company, to generate and ... light chains(H2L2) using one of Harbour,s transgenic mouse ...
Cached Biology Technology:Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 2Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 3Cebix's Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes 2Cebix's Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes 3Harbour Antibodies BV Signs Research and Licence Agreement With Lilly 2
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... The next big thing in medical diagnostics could ... the material from which sand is formed, silicon dioxide. ... 230 nanometers across, can be used to trap antibodies ... the bacteria that causes potentially lethal diarrhea. According ...
... current check for kidney disease is a simple blood test ... days for this metabolite to accumulate to levels that are ... it may be too late to intervene. To close ... scientists and physicians led by Dr. Jonathan Barasch, M.D., Ph.D., ...
... few better-known proteins than nestin, whose very presence in an ... a neural stem cell. As helpful as this is to ... in a cell. In a study published in the ... , Salk Institute of Biological Studies investigators led by Kuo-Fen ...
Cached Biology News:Detecting lethal diseases with rust and sand 2Seeing kidney injury, as it happens 2Salk researchers discover that stem cell marker regulates synapse formation 2Salk researchers discover that stem cell marker regulates synapse formation 3
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: